Vicki Belo

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease

Retrieved on: 
Thursday, October 12, 2023
Health, Genetics, Clinical Trials, General Health, Cardiology, Biotechnology, Annual general meeting, Diagnosis, UIP, Physician, American College of Chest Physicians, Radiology, American College, ILD, Connective tissue, Idiopathic pulmonary fibrosis, HRCT, UCLA Health, CT, Vicki Belo, Interstitial lung disease, Scar, Disorder, Fibrosis, Patient, Medical imaging, Medical device, Pulmonology

(Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic Classifier, which is used by physicians to improve diagnostic and prognostic confidence of interstitial lung diseases (ILDs).

Key Points: 
  • (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic Classifier, which is used by physicians to improve diagnostic and prognostic confidence of interstitial lung diseases (ILDs).
  • The studies also underscore the challenge of identifying usual interstitial pneumonia (UIP) in patients being evaluated for ILD.
  • The studies presented at the CHEST Annual Meeting show that adding the Envisia Genomic Classifier to the diagnostic process can improve the ability to detect UIP.
  • For patients with indeterminate HRCT results, adding the Envisia Genomic Classifier more than doubled the UIP diagnostic yield to 49%.

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC MODEL OF SARCOIDOSIS AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Wednesday, June 21, 2023
Sarcoidosis, TSC2, Myelocyte, Heart, Mouse, Granuloma, Cleveland Clinic, MOUSE, OH, Medical school, CARDIAC, Fibroblast, Medical University of Vienna, Pulmonology, Fibrosis, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Vicki Belo, Interstitial lung disease, Extracellular matrix, Biology, Matrix, Poster, Cleveland, Conference, Disease, Vaccine, Pharmaceutical industry, Medical device, Genetics, Foresight

MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.

Key Points: 
  • MMP-12 might therefore be required for granuloma formation and persistence, and further implicates a role of MMP-12 in cardiac fibrosis.
  • The role of MMP-12 and its therapeutic implications may extend to other aspects of sarcoidosis and interstitial lung diseases.
  • TAIPEI, June 21, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • Fibrotic collagen deposition was significantly reduced, as well as the total number of activated fibroblasts in the whole heart.

FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Friday, June 16, 2023
Sarcoidosis, MOUSE, Asthma, CARDIAC, Biomarker, Foresight, International Conference on Emerging Infectious Diseases, Poster, Patient, Interstitial lung disease, Vicki Belo, IND, Conference, Pharmaceutical industry

TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.

Key Points: 
  • Poster on FP-020, a follow-on, best-in-class, oral MMP-12 inhibitor in a genetic model of sarcoidosis includes efficacy, biomarkers and complete translational cellular profiling supporting novel anti-inflammatory and anti-fibrotic mechanism
    TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • "We are very excited to have the opportunity to present such compelling data related to FP-020 in this sarcoidosis model.
  • The data strongly supports the role of MMP-12 in sarcoidosis disease biology and further strengthens our view on the promise of our MMP-12 inhibitors for sarcoidosis and ILDs" said Dr. Wenjin Yang, Chief Scientific Officer at Foresee.
  • The poster will be available to view during the WASOG conference, Tuesday June 20, 2023 and available after the conference.

FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION AT THE WASOG 2023 INTERNATIONAL CONFERENCE ON SARCOIDOSIS AND INTERSTITIAL LUNG DISEASES (ILDs)

Retrieved on: 
Friday, June 16, 2023
Sarcoidosis, MOUSE, Asthma, CARDIAC, Biomarker, Foresight, International Conference on Emerging Infectious Diseases, Poster, Patient, Interstitial lung disease, Vicki Belo, IND, Conference, Pharmaceutical industry

TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.

Key Points: 
  • Poster on FP-020, a follow-on, best-in-class, oral MMP-12 inhibitor in a genetic model of sarcoidosis includes efficacy, biomarkers and complete translational cellular profiling supporting novel anti-inflammatory and anti-fibrotic mechanism
    TAIPEI, June 16, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the company will be participating and presenting a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs), taking place June 19-21, 2023 in Stockholm, Sweden.
  • "We are very excited to have the opportunity to present such compelling data related to FP-020 in this sarcoidosis model.
  • The data strongly supports the role of MMP-12 in sarcoidosis disease biology and further strengthens our view on the promise of our MMP-12 inhibitors for sarcoidosis and ILDs" said Dr. Wenjin Yang, Chief Scientific Officer at Foresee.
  • The poster will be available to view during the WASOG conference, Tuesday June 20, 2023 and available after the conference.

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Retrieved on: 
Wednesday, May 24, 2023
Oncology, Health, Health Technology, Genetics, Other Health, Clinical Trials, Biotechnology, CT, Lung nodule, University, HRCT, ATS, University of Washington Medical Center, UIP, Cancer, Lung cancer, ILD, FVC, American Thoracic Society, Interstitial lung disease, Restrictive lung disease, Vital capacity, Patient, Physician, Risk, Vicki Belo, Diagnosis, IPF, Massachusetts General Hospital, Idiopathic pulmonary fibrosis, Medical device, Pharmaceutical industry, Medical imaging

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.
  • The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C.
  • For Veracyte’s Percepta Nasal Swab, researchers presented updated preliminary study findings showing the test’s potential to better stratify the risk of lung cancer for patients with lung nodules.
  • “Importantly, these findings suggest that our tests in interstitial lung disease and lung cancer are performing as intended.”

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Retrieved on: 
Tuesday, May 9, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Tissue, Graft-versus-host disease, Heart, SingHealth, Partnership, Boehringer, Doctor of Philosophy, Neoplasm, Infection, Survival, Pharmacokinetics, Quality of life, Scar, PDE4B, Inflammation, DSM-IV codes, Lung, Pulmonary fibrosis, Boehringer Ingelheim, Duke–NUS Medical School, Fibrosis, Death, Discovery, Patient, Vicki Belo, Circulatory system, Biology, Liver, IPF, Safety, Pharmaceutical industry

Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.

Key Points: 
  • Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.
  • The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte.
  • ‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues.
  • Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis.

Pulmonary Fibrosis Foundation Announces PFF Community Registry Recruitment Month in April

Retrieved on: 
Monday, April 3, 2023
DNA, Employment, Registry, Education, Friends, Cystic Fibrosis Foundation, Scar, ILD, Roche, Research, Inflammation, Lung, MS, Rockcastle Regional Hospital and Respiratory Care Center, Boehringer Ingelheim, Pulmonary fibrosis, Patient, Physician, CCN, Vicki Belo, Diagnosis, DNA methylation, PFF, Health, United Therapeutics, PF, Idiopathic pulmonary fibrosis, Social media, Caregiver, Disease, Engineered wood, Nursing, Asset management, Medical device, Genentech, MD

CHICAGO, April 3, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announces that April is PFF Community Registry Recruitment Month with activities including an educational webinar, social media content, and a journal club discussion for healthcare providers in the PFF Care Center Network (CCN).

Key Points: 
  • CHICAGO, April 3, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announces that April is PFF Community Registry Recruitment Month with activities including an educational webinar, social media content, and a journal club discussion for healthcare providers in the PFF Care Center Network (CCN).
  • Since its launch in July 2022, more than 1,200 individuals have joined the PFF Community Registry.
  • PFF Community Registry Recruitment Month will include communications to mobilize those in the PF community to share information and recruit peers, patients, friends, and family members.
  • The PFF Community Registry is part of the PFF Registry program, which consists of two databases.

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress

Retrieved on: 
Thursday, March 30, 2023
ARG1, Sarcoidosis, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, CET, Therapy, Medical device, American Association for Cancer Research, NASH, Switzerland, Clinical trial, European Directive on Traditional Herbal Medicinal Products, Cancer, CTA, RNA, Inflammation, Language, EMA, Fibrosis, Biocidal Products Directive, Congress, Patient, Vicki Belo, Interstitial lung disease, ARG2, Biology, Growth, Fatty liver disease, MOC, FDA, Leukemia, IPF, Molecular Cancer Research, Idiopathic pulmonary fibrosis, Safety, Disease, Pharmaceutical industry, Cryptocurrency, MD, Polish

“Molecure has made significant progress over 2022, becoming a clinical stage biotechnology company preparing our two most advanced assets to start multi-center phase I and phase II studies respectively” said Marcin Szumowski, CEO and President of the Management Board of Molecure.

Key Points: 
  • “Molecure has made significant progress over 2022, becoming a clinical stage biotechnology company preparing our two most advanced assets to start multi-center phase I and phase II studies respectively” said Marcin Szumowski, CEO and President of the Management Board of Molecure.
  • In recent weeks, we achieved an important milestone dosing the first cancer patient in a Phase I study with OATD-02, the first and only dual arginase inhibitor.
  • The Company's full year presentation to investors will be held on April 5, 2023 at 2:00 PM (CET) in an online meeting.
  • In 2022, Molecure announced a new name and brand identity.

Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference

Retrieved on: 
Monday, December 19, 2022
United, Prurigo nodularis, Route of administration, Nalbuphine, Interstitial lung disease, Trevi, Partnership, Itch, Risk, Conference, Chronic cough, Vicki Belo, Safety, DEA, IPF, Therapy, Idiopathic pulmonary fibrosis, Cough, Pharmaceutical industry

NEW HAVEN, Conn., Dec. 19, 2022  /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior leadership will attend and present at the following investor and partnership conferences in January. These events will take place in San Francisco during the week of the annual J.P. Morgan Health Care Conference.

Key Points: 
  • These events will take place in San Francisco during the week of the annual J.P. Morgan Health Care Conference.
  • Biotech Showcase 2023 (January 9-11, 2023)
    For more information or to register, please click here .
  • Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).
  • The ĸ- and µ-opioid receptors are centrally and peripherally active and known to be critical mediators of cough and itch.